RT Journal Article
T1 The anti-inflammatory mediator, vasoactive intestinalpeptide, modulates the differentiation and function of ThSubsets in rheumatoid arthritis
A1 Villanueva Romero, Raúl
A1 Gutiérrez Cañas, Irene
A1 Carrión Caballo, Mar
A1 Pérez García, Selene
A1 Seoane Valiño, Iria V.
A1 Martínez, Carmen
A1 Gomáriz, Rosa P.
A1 Juarranz Moratilla, Yasmina
AB Genetic background, epigenetic modifications, and environmental factors trigger autoimmune response in rheumatoid arthritis (RA). Several pathogenic infections have been related to the onset of RA and may cause an inadequate immunological tolerance towards critical self-antigens leading to chronic joint inflammation and an imbalance between different T helper (Th) subsets. Vasoactive intestinal peptide (VIP) is a mediator that modulates all the stages comprised between the arrival of pathogens and Th cell differentiation in RA through its known anti-inflammatory and immunomodulatory actions. This “neuroimmunopeptide” modulates the pathogenic activity of diverse cell subpopulations involved in RA as lymphocytes, fibroblast-like synoviocytes (FLS), or macrophages. In addition, VIP decreases the expression of pattern recognition receptor (PRR) such as toll-like receptors (TLRs) in FLS from RA patients. These receptors act as sensors of pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern (DAMP) connecting the innate and adaptive immune system. Moreover, VIP modulates the imbalance between Th subsets in RA, decreasing pathogenic Th1 and Th17 subsets and favoring Th2 or Treg profile during the differentiation/polarization of naïve or memory Th cells. Finally, VIP regulates the plasticity between theses subsets. In this review, we provide an overview of VIP effects on the aforementioned features of RA pathology.
PB Hindawi
SN 2314-8861, ESSN: 2314-7156
YR 2018
FD 2018
LK https://hdl.handle.net/20.500.14352/18811
UL https://hdl.handle.net/20.500.14352/18811
LA eng
NO Instituto de Salud Carlos III/FEDER
NO RETICS
NO Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER)
DS Docta Complutense
RD 6 may 2024